Moderna (MRNA) shares fell more than 19% in premarket activity Monday after the company said it now expects 2025 revenue to be between $1.5 billion and $2.5 billion, down from the previous range of $2.5 billion to $3.5 billion.
Analysts surveyed by FactSet expect $2.92 billion.
The drugmaker said it is accelerating its cost efficiency and prioritization programs, with projected cash cost reductions of $1 billion in 2025.
The company said it expects to end 2025 with cash and investments of about $6 billion.
Moderna will report its Q4 financial results on Feb. 14.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。